Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 662,205 | 660,672 | 431,526 | 383,824 | 456,264 |
| Marketable Securities | 334,473 | 459,533 | 418,830 | 376,714 | 387,736 |
| Receivables | 419,424 | 392,672 | 392,443 | 464,847 | 372,348 |
| Inventories | 622,253 | 554,007 | 583,815 | 594,804 | 524,961 |
| Other current assets | 10,859 | 10,940 | 9,615 | 10,325 | 12,201 |
| TOTAL | $2,139,835 | $2,180,155 | $2,023,478 | $1,976,649 | $1,844,524 |
| Non-Current Assets | |||||
| PPE Net | 491,371 | 499,339 | 508,690 | 493,496 | 488,614 |
| Investments And Advances | 9,561,140 | 4,638,205 | 2,655,709 | 1,027,736 | 830,790 |
| Intangibles | 491,413 | 409,656 | 352,893 | 680,182 | 638,724 |
| Other Non-Current Assets | 288,856 | 281,505 | 70,298 | 94,949 | 47,852 |
| TOTAL | $10,832,780 | $5,828,705 | $3,587,590 | $2,296,363 | $2,005,980 |
| Total Assets | $12,972,620 | $8,008,859 | $5,611,068 | $4,273,012 | $3,850,504 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,798 | 426,172 | 493 | 420 | N/A |
| Accounts payable and accrued liabilities | 139,451 | 107,014 | 122,450 | 135,182 | 133,109 |
| Accrued Expenses | 222,875 | 180,084 | 143,510 | 171,632 | 163,364 |
| Other current liabilities | 131,102 | 86,840 | 101,218 | 127,288 | 115,388 |
| TOTAL | $631,536 | $905,495 | $450,795 | $502,696 | $471,322 |
| Non-Current Liabilities | |||||
| Long Term Debt | 12,258 | 13,579 | 438,937 | 434,581 | 434,186 |
| Deferred Revenues | 42,468 | 33,735 | 26,936 | 28,233 | 31,003 |
| Other Non-Current Liabilities | 372,099 | 336,941 | 147,766 | 183,276 | 140,537 |
| TOTAL | $2,461,142 | $1,348,307 | $1,139,942 | $840,066 | $800,022 |
| Total Liabilities | $3,092,678 | $2,253,802 | $1,590,737 | $1,342,762 | $1,271,344 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,844 | 29,925 | 29,800 | 29,805 | 29,577 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 9,268,012 | 5,470,779 | 3,722,073 | 1,830,439 | 1,828,581 |
| Other shareholders' equity | 282,549 | -87,745 | -47,087 | 738,577 | 417,665 |
| TOTAL | $9,879,940 | $5,755,057 | $4,020,331 | $2,930,250 | $2,579,160 |
| Total Liabilities And Equity | $12,972,618 | $8,008,859 | $5,611,068 | $4,273,012 | $3,850,504 |